Drapeau France                     Drapeau espagne                    Drapeau UK                  drapeau américain             drapeau émirats
Home white on blue 32x32 SITE MAP   DR. GEORGES DEBLED TV-VIDEOS BOOKS  
 ANTI AGING SOLUTIONS FOR  WOMAN
 

 

 Errors in  “menopause” treatment

The menopause disease

The random administration of estrogens associated or not with progesterone or progestogens HRT (hormonal replacement therapy) are dedicated to failure and have even noxious effects.

FAILURE OF “HORMONAL TREATMENTS” (HRT = Hormonal Replacement Therapy) AMONG MENOPAUSED WOMEN

 The “WOMENS' HEALTH INITIATIVE” is a15-year project involves over 161,000 women ages 50-79, and is one of the most definitive, far reaching programs of research on women's health ever undertaken in the U.S. (http://www.whi.org )

Results of the first HRT study on “Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women” were published in 2002 (JAMA. 2002;288:321-333) (5).

The conclusions about this randomized clinical trial of great scale relating to 16,608 old women from 50 to 79 years treated by Progestin (2.5 mg of medroxyprogesterone acetate) and estrogens (0,625 Mg of combined estrogens “equine”) were: (table 5).

The study was to proceed until 2005. It was stopped after a 5.2 years average of follow-up on July 9th, 2002.

It was decided to continue the treatment containing estrogens alone among women with prior hysterectomy http://www.whi.org

 

WOMEN TAKING ESTROGEN PLUS PROGESTIN RELATIVE TO PLACEBO

JAMA. 2002;288:321-333 (5)

Stroke rates increased by 41%

CHD (coronary heart disease) events was increased by 29%

Venous thromboembolism (VTE) 2-fold greater

Total cardiovascular disease increased by 22%

Breast cancer increased by 26%


WOMEN WITH PRIOR HYSTERECTOMY aged 50-79 years

The Women’s Health Initiative (WHI) Estrogen Alone (E-Alone) Trial was designed to assess the health benefits and risks of estrogen use in healthy postmenopausal women. In the WHI E-Alone Trial, 10,739 women with prior hysterectomy, aged 50-79 years, were assigned to take either estrogen alone (conjugated estrogens [Premarin®]) or inactive (placebo) study pills. The National Institutes of Health stopped the E-Alone Trial ahead of schedule in February 2004 primarily because of an increased stroke risk for women taking study pills with estrogen alone

The pharmaceutical industry

·         Even after the Women's Health Initiative (WHI) found that the risks of menopausal hormone therapy (hormone therapy) outweighed benefit for asymptomatic women, about half of gynecologists in the United States continued to believe that hormones benefited women's health. The pharmaceutical industry has supported publication of articles in medical journals for marketing purposes (6).

 

·         In June 2011 the U.S. Supreme Court refused to hear a Pfizer Inc. unit’s appeal of a $58 million award in a case against Premarin (estrogens) and Prempro (estrogens plus medroxyprogesterone acetate) menopause drugs.

Three Nevada women who contracted breast cancer after taking the company’s menopause drugs were awarded the amount in a 2007 case.

 

·         The rebuff leaves the amount as the largest to be upheld on appeal in thousands of hormone-replacement drug suits. Over six million women took Prempro and other menopause drugs before a 2002 study pointed out their links to cancer. At one point Pfizer and his units faced more than 10,000 claims, according to lawyers for former users

G. Debled. The menopause disease. Approaches to aging control : 19:17-24,October 2015

The menopause disease .pdf  Octobre 2015.    SEMAL Madrid